Date published: 2026-5-17

1-800-457-3801

SCBT Portrait Logo
Seach Input

CAPS2 Inhibitors

Chemical inhibitors of CAPS2 operate through a variety of mechanisms to disrupt its function in vesicle exocytosis and neurotransmitter release. BAPTA-AM, a calcium chelator, enters cells in a membrane-permeable form and, once inside, binds to calcium ions, thus inhibiting CAPS2 by depriving it of the calcium necessary for its role in vesicle exocytosis. Similarly, inhibitory chemicals such as ω-Conotoxin GVIA and ω-Agatoxin IVA target specific calcium channels. ω-Conotoxin GVIA blocks N-type calcium channels, preventing calcium influx, while ω-Agatoxin IVA targets P/Q-type calcium channels, both crucial for the calcium-dependent activation of CAPS2 in neurotransmitter release. SNX-482 also plays a role in this context by inhibiting R-type calcium channels, which are involved in the regulation of CAPS2-mediated vesicle trafficking.

Further into the cellular mechanism, ML-9 inhibits myosin light chain kinase, which is essential for actin-myosin interactions. This inhibition disrupts the cytoskeletal dynamics necessary for vesicle movement, a process in which CAPS2 is involved. Thapsigargin contributes to the inhibition by targeting the SERCA pump, leading to the depletion of intracellular calcium stores and therefore reducing the calcium-dependent vesicle release facilitated by CAPS2. The small molecule Exo1 disrupts SNARE-complex formation, which is essential for vesicle fusion to the plasma membrane, a process in which CAPS2 is implicated. Tetanus Toxin and Clostridium Botulinum Neurotoxin A achieve inhibition by targeting components of the SNARE complex; Tetanus Toxin cleaves synaptobrevin, which is critical for the fusion of vesicles at the plasma membrane in neurotransmitter release, a process regulated by CAPS2. Lastly, Dynasore inhibits the GTPase activity of dynamin, blocking vesicle scission, while Endosidin 2 inhibits exocyst complex assembly, and Latrunculin A binds to actin, preventing its polymerization, all of which are essential for the proper functioning of CAPS2 in vesicle trafficking and neurotransmitter release.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

BAPTA/AM

126150-97-8sc-202488
sc-202488A
25 mg
100 mg
$138.00
$458.00
61
(2)

BAPTA-AM is a cell-permeable calcium chelator. It inhibits CAPS2 by chelating intracellular calcium that is necessary for CAPS2-mediated vesicle exocytosis.

ω-Agatoxin IVA

145017-83-0sc-302015
100 µg
$463.00
(0)

ω-Agatoxin IVA is a P/Q-type calcium channel blocker. It inhibits CAPS2 by inhibiting calcium channels that provide the calcium ions required for CAPS2's function in vesicle priming.

ML-9

105637-50-1sc-200519
sc-200519A
sc-200519B
sc-200519C
10 mg
50 mg
100 mg
250 mg
$112.00
$449.00
$673.00
$1224.00
2
(1)

ML-9 is a kinase inhibitor that can inhibit myosin light chain kinase (MLCK). It inhibits CAPS2 by disrupting the actin-myosin interactions which are essential for vesicle movement and secretion involving CAPS2.

Thapsigargin

67526-95-8sc-24017
sc-24017A
1 mg
5 mg
$136.00
$446.00
114
(2)

Thapsigargin is a SERCA pump inhibitor, which leads to depletion of intracellular calcium stores. This inhibits CAPS2 by reducing the calcium-dependent vesicle release that CAPS2 facilitates.

Exo1

461681-88-9sc-200752
sc-200752A
10 mg
50 mg
$84.00
$297.00
4
(1)

Exo1 is a small molecule that inhibits exocytosis. It inhibits CAPS2 function by disrupting the SNARE-complex formation which is essential for vesicle fusion to the plasma membrane, a process where CAPS2 is involved.

Dynamin Inhibitor I, Dynasore

304448-55-3sc-202592
10 mg
$89.00
44
(2)

Dynasore is a dynamin inhibitor, which inhibits the GTPase activity of dynamin. It inhibits CAPS2 by blocking vesicle scission from the donor membrane, which is essential for CAPS2's function in vesicle trafficking.

Latrunculin A, Latrunculia magnifica

76343-93-6sc-202691
sc-202691B
100 µg
500 µg
$265.00
$815.00
36
(2)

Latrunculin A binds to actin and prevents its polymerization. It inhibits CAPS2 by disrupting the cytoskeletal dynamics necessary for vesicle transport and secretion processes involving CAPS2.